Macrodosing mushrooms means taking a full psychedelic dose of psilocybin-containing mushrooms, typically 2 to 5 grams of dried Psilocybe cubensis, intended to produce the complete psychedelic experience rather than the sub-perceptual effects of a microdose. The term emerged in the early 2010s in psychedelic harm-reduction circles as a counterpart to “microdose,” which had entered common usage around 2011 after a series of articles by psychiatrist James Fadiman. A macrodose lasts four to six hours, costs the participant a full day of altered consciousness, and is the dose level used in the psilocybin-assisted therapy trials at institutions like Johns Hopkins and Imperial College London.
This article covers what counts as a macrodose, how it differs from microdosing in practice and intent, what the experience feels like, how the brain responds, the preparation that typically goes into a session, the benefits people report and the risks that follow, the safety profile, and the legal status in Canada. It is written as a practical reference for people researching the term, not as encouragement to use it.
A macrodose of dried Psilocybe cubensis is generally 2 to 5 grams. Within that range, harm-reduction sources usually break it into three tiers. A low macrodose is 2 to 2.5 grams, enough to produce a clear psychedelic experience with manageable intensity. A standard macrodose is 2.5 to 3.5 grams, the dose most often used in clinical research and described in classic psychedelic literature. A high macrodose is 3.5 to 5 grams, intense and demanding, often called a “heroic dose” after Terence McKenna’s “five dried grams in silent darkness” formulation. Anything above 5 grams is rare outside committed psychonaut circles and significantly raises the risk of difficult experiences.
The exact gram equivalent varies by strain. Penis Envy and Albino Penis Envy, both substantially more potent than the cubensis average, require roughly half the weight to reach the same intensity. Golden Teacher, B+, Mazatapec, and most other commonly sold cubensis strains fit the gram ranges above. Equivalent doses of pure psilocybin in clinical research are typically 25 to 30 milligrams for a standard macrodose, which corresponds roughly to 3 grams of dried cubensis.
A macrodose is the opposite of a microdose in both quantity and intent. A microdose is typically one-tenth of a standard dose, around 0.1 to 0.3 grams of dried mushrooms, taken specifically to fall below the threshold of obvious perceptual change. A macrodose is taken specifically to cross that threshold. The two practices share a substance and very little else.
A useful frame: microdosing is for the rest of the day, macrodosing is the day. Microdoses are often taken on a schedule (Fadiman’s original protocol was once every three days) and incorporated into normal work and life. Macrodoses are planned events, with a cleared schedule, a chosen setting, and ideally a sober companion or trip sitter.
A microdose of Psilocybe cubensis is approximately 0.1 to 0.3 grams of dried fruit body, taken at intervals (commonly every third day, every other weekday, or some structured rotation) over several weeks. The intent is to produce no obvious change in perception or behaviour while introducing a small amount of psilocybin into the system. Users who feel obvious effects from their dose are usually advised to reduce it, since the practice loses its functional character once perception shifts noticeably.
Research on microdosing has grown rapidly but is still in early stages. Placebo-controlled trials have produced mixed results: some find measurable improvements in mood and cognitive performance, others find that expectation accounts for most of the reported benefits. The honest summary is that microdosing may produce real but small effects, the size and reliability of which are still being worked out.
Five practical differences matter. First, dose: roughly one-tenth versus full. Second, intent: subtle integration versus full psychedelic experience. Third, schedule: regular intervals versus occasional planned sessions. Fourth, setting: ordinary daily life versus a cleared, prepared environment. Fifth, support: no sitter needed versus a sober companion strongly recommended.
The pharmacology is the same substance. According to the National Institute on Drug Abuse, “when a person takes psilocybin, their body converts it to another substance, psilocin,” and psilocin binds to the brain’s serotonin 5-HT2A receptors at any dose. The difference between a microdose and a macrodose is how many of those receptors get activated and for how long, not which receptors or which compound.
At macrodose levels, psilocin binding to 5-HT2A receptors in cortical pyramidal neurons produces measurable changes across the brain. Functional MRI studies show the default mode network, the brain network associated with self-referential thinking and habitual rumination, becomes less internally coordinated during a macrodose. At the same time, communication between brain regions that do not normally talk much to each other increases. The net effect is a temporary state in which usual patterns of thought become more flexible and unusual associations form more easily.
The National Center for Complementary and Integrative Health notes that “psilocybin combined with psychotherapy may be safe and effective for improving anxiety, depression, and existential distress,” and the working hypothesis is that the brain’s temporary flexibility during a macrodose creates a window in which therapeutic insight is more accessible than usual. Whether that mechanism explains the persistent mood improvements reported in trials is still being investigated.
The benefits people report from macrodosing fall into three broad categories: subjective insight, emotional release, and lasting mood change. Many users describe a single high-dose session as producing perspective shifts they had been unable to reach through years of conversation or reflection. Others describe emotional release: tears, laughter, the surfacing of long-buried memories, the felt sense of letting go of a grudge or a fear. A smaller subset report measurable changes in mood, anxiety, or addictive patterns that persist for weeks or months after the session.
The clinical research supports a meaningful version of these claims. Studies at Johns Hopkins, NYU, and Imperial College London have shown that one or two macrodose-equivalent psilocybin sessions, paired with structured psychotherapy, can produce sustained reductions in depression and anxiety in patients with treatment-resistant conditions or with terminal cancer. The honest caveat: clinical trial benefit happens in a setting with extensive preparation, integration, and trained therapists. Recreational macrodosing without that scaffolding produces a wider range of outcomes, including positive ones, but is not the same intervention.
The most common acute risk is a bad trip: an extended period of fear, anxiety, paranoia, or psychological discomfort during the four-to-six-hour window of effects. Bad trips are more likely with higher doses, unfamiliar settings, untreated anxiety, or the absence of a sober sitter. They are usually managed by changing setting, drinking water, lying down, and waiting them out, but they can be severe enough to require medical reassurance and they can leave lasting psychological residue if not processed afterward.
A smaller but real risk is the worsening or surfacing of latent psychological conditions. People with personal or family histories of psychosis or bipolar disorder are generally excluded from clinical trials of psilocybin because of the documented risk that a macrodose could trigger or worsen those conditions. A subset of users develop Hallucinogen Persisting Perception Disorder, in which visual changes from the original experience recur sporadically for weeks or months.
Physical risks at macrodose are mostly mild: raised blood pressure and heart rate, nausea and vomiting in the first hour, and the practical danger of impaired judgement during the experience. Pure psilocybin has not been reliably linked to fatal overdose. Mixing macrodose psilocybin with other drugs (alcohol, cannabis, stimulants, lithium, MAOIs, SSRIs) is particularly important to avoid because the combinations are unpredictable and in some cases medically serious.
Preparation has three components: mental, environmental, and logistical. Mental preparation usually means setting an intention for the session (not a specific outcome, but a question or area of attention to bring in), spending the day or week beforehand in a relatively settled state, and avoiding the session if currently in acute crisis. Environmental preparation means choosing a familiar, safe space with comfortable seating, lighting that can be dimmed, a music playlist queued in advance, water and a light snack available, and the front door secured against interruption.
Logistical preparation means clearing the calendar for the full day (not just the trip window), arranging a sober trip sitter who knows what is happening and can be present without intruding, eating a light meal an hour or two before the session, and saving the number for a psychedelic peer-support hotline like the Fireside Project. Time of day matters: sessions started in the morning end before bedtime, which makes integration and sleep easier than sessions started in the afternoon.
Dried mushrooms eaten on a relatively empty stomach take thirty to sixty minutes to take effect. Tea brewed from ground mushrooms can come on faster, often within twenty to thirty minutes, because the psilocybin is already in solution. Capsules take longest, ninety minutes or more, because the capsule must dissolve before the mushroom material itself begins to digest.
Peak intensity follows onset by about sixty to ninety minutes. The plateau holds for one to two hours, then the comedown stretches over another two to three hours. A quiet residual phase typically lingers for the rest of the day. The total duration is four to six hours of active effects, regardless of the form ingested.
The safety profile of psilocybin macrodosing in healthy adults, in controlled settings, with screening, preparation, and integration, is unusually good for a drug at this intensity level. Clinical trials at major research institutions have run hundreds of sessions with serious adverse events reported in well under one percent of cases. Outside the clinical setting, the safety picture is more variable. The substance is the same; what differs is screening, dosage accuracy, setting, and the presence of a sober supporting person.
The clear contraindications are: personal or family history of psychosis or bipolar disorder, current use of MAOIs or lithium, severe cardiovascular disease, and the acute phase of major depression with active suicidal ideation. The relative contraindications are: pregnancy, current SSRI use (which blunts effects rather than producing harm but complicates dosing), and the absence of any sober support during the session.
Four to six hours of active effects, with onset thirty to sixty minutes after ingestion, peak intensity sixty to ninety minutes after onset, and a comedown phase of two to three hours. A residual quiet, introspective phase commonly lingers for the rest of the day.
Yes, quickly. Psilocybin tolerance builds within hours of a dose and takes several days to a week to reset fully. Taking a second macrodose within a few days produces a substantially weaker experience. Most users space macrodoses several weeks or months apart.
No. Psilocybin and psilocin are Schedule III substances under Canada’s Controlled Drugs and Substances Act. Possession, production, and trafficking carry criminal penalties, with narrow exceptions for Health Canada’s Special Access Programme, Section 56 exemptions, and authorised clinical trials.
A light meal one to two hours before the session reduces the chance of nausea while allowing the dose to take effect within a reasonable window. Eating a heavy meal closer to the dose slows onset substantially and can blunt peak intensity. Eating nothing for a full day beforehand sometimes intensifies nausea.
Change the conditions and wait. Lower the lights, change to slower music, move to a different room, drink water, breathe slowly, talk to your sitter calmly. Bad trips are time-limited by the pharmacology of psilocybin and almost always resolve before the four-to-six-hour window is over. The threshold for calling for medical help is uncontrollable panic that does not respond to calming measures, chest pain, fainting, or any suggestion the substance was not what was thought.
